Adecto Pharmaceuticals files a U.S. provisional patent application on humanized ADAM8 monoclonal antibodies

BOSTON, Mass. (August 11, 2026) - Adecto Pharmaceuticals today announced that it has successfully filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO). The application protects a number of novel, highly specific ADAM8 inhibitory humanized monoclonal antibodies, including the company’s lead therapeutic AD100.

Conventional immunotherapies often fail because they activate only T lymphocytes - a small subset of the body’s immune defenses. The cell surface protein ADAM8 has been implicated in broad immune cell dysfunction in numerous aggressive cancer types. By targeting ADAM8 for inhibition, Adecto’s therapy aims to reprogram both lymphoid and myeloid cells, generating a more potent anti-tumor immune response to efficiently kill cancer cells, including those resistant to conventional immunotherapy.
"
"Filing this provisional patent application marks an essential milestone in our roadmap to delivering the first-in-class ADAM8-targeting immunotherapy for patients with very limited options," said Dr. Nora D. Mineva, Co-Founder, CEO, and Chief Scientist of Adecto Pharmaceuticals.

The newly filed provisional application covers composition-of-matter of the humanized antibody candidates as well as safety aspects of the therapeutic lead and of ADAM8 itself as a target, adding critical breadth to the company's existing preclinical validation dataset.


About Adecto Pharmaceuticals
Adecto Pharmaceuticals is a biotechnology company specializing in the development of targeted therapies and diagnostics for ADAM8-positive cancers. Founded in 2014 by Tufts researchers, the company is dedicated to stopping primary cancer growth and metastasis.